Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Radiotherapy Consolidation Reduces Risk of Relapse in Diffuse Large B-Cell Lymphoma Patients with Bulky Disease in Complete Response after Frontline Immunochemotherapy: Results from a Retrospective Single Center Study

Corrado Benevolo Savelli, Mattia Novo, Francesco Vassallo, Andrea Evangelista, Matteo Bisio, Luca Legato, Veronica Peri, Michele Clerico, Mario Levis, Sara Bartoncini, Chiara Cavallin, Maura Nicolosi, Carola Boccomini, Lorella Orsucci, Federica Cavallo, Benedetto Bruno, Roberto Freilone, Umberto Ricardi, Barbara Botto

Blood (2023) 142 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2023-184510

Published: 2023

Journal Articles

Clinical Outcomes of 420 MDS Patients Treated with 5-Azacytidine: Evaluation of Overall Survival, Duration of Treatment and Rate of Discontinuation in a Real Life Study from the Italian MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM)

Blood (2016) 128 (22): 4341.

https://doi.org/10.1182/blood.V128.22.4341.4341

Published: 2016

Journal Articles

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2015) 126 (23): 2735.

https://doi.org/10.1182/blood.V126.23.2735.2735

Published: 2015

Journal Articles

The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP

Barbara Botto, Domenico Novero, Annalisa Chiappella, Mattia Novo, Alessia Castellino, Chiara Ciochetto, Giovanni Cametti, Andrea Evangelista, Roberto Freilone, Paola Ghione, Marco Ladetto, Paola Riccomagno, Federico Vittone, Giovannino Ciccone, Umberto Vitolo

Blood (2014) 124 (21): 2964.

https://doi.org/10.1182/blood.V124.21.2964.2964

Published: 2014

Journal Articles

A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study

Blood (2013) 122 (21): 745.

https://doi.org/10.1182/blood.V122.21.745.745

Published: 2013

Journal Articles

Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi

Blood (2013) 122 (21): 5088.

https://doi.org/10.1182/blood.V122.21.5088.5088

Published: 2013

Journal Articles

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Blood (2012) 120 (21): 2720.

https://doi.org/10.1182/blood.V120.21.2720.2720

Published: 2012

Journal Articles

The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi

Blood (2011) 118 (21): 2651.

https://doi.org/10.1182/blood.V118.21.2651.2651

Published: 2011

Journal Articles

Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi

Blood (2011) 118 (21): 2636.

https://doi.org/10.1182/blood.V118.21.2636.2636

Published: 2011

Journal Articles

High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study

Daniela Cilloni, MD, PhD, Emanuela Messa, Lucia Biale, MD, Margherita Bonferroni, MD, Flavia Salvi, MD, Monia Lunghi, M.D., Bernardino Allione, Dario Ferrero, Roberto Freilone, MD, Alessandro Levis, MD, Giuseppe Saglio

Blood (2011) 118 (21): 611.

https://doi.org/10.1182/blood.V118.21.611.611

Published: 2011

Journal Articles

Radioimmunotherapy (RIT) with 90 yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL)

Barbara Botto, MD, Chiara Ciochetto, Marilena Bellò, Roberto Passera, Giulia Benevolo, MD, Carola Boccomini, MD, Annalisa Chiappella, Roberto Freilone, Francesca Giunta, Maura Nicolosi, Erika Orlandi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, MD, Anna Tonso, Gianni Bisi, Umberto Vitolo, MD

Blood (2011) 118 (21): 3107.

https://doi.org/10.1182/blood.V118.21.3107.3107

Published: 2011

Journal Articles

Prognostic Impact of Comorbidities In A Cohort of 788 MDS Patients Based On A CIRS-G Derived Score. A MDS Piedmont Registry Prospective Study

Emanuela Messa, Daniela Gioia, Claudia Bertassello, Gianni Ciccone, Bernardino Allione, Daniela Cilloni, MD, PhD, Flavia Salvi, MD, Gianni Cametti, Monia Lunghi, Dario Ferrero, Roberto Freilone, MD, Margherita Bonferroni, Giuseppe Saglio, MD, Alessandro Levis, MD

Blood (2011) 118 (21): 1729.

https://doi.org/10.1182/blood.V118.21.1729.1729

Published: 2011

Journal Articles

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Blood (2011) 118 (21): 1606.

https://doi.org/10.1182/blood.V118.21.1606.1606

Published: 2011

Journal Articles

Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL)

Annalisa Chiappella, Patrizia Pregno, Pier Luigi Zinzani, Andrea Evangelista, Alberto Fabbri, Fabio Facchetti, Andres JM Ferreri, Silvia Franceschetti, Roberto Freilone, Livio Gargantini, Daniela Gioia, Anna Marina Liberati, Maura Nicolosi, Lorella Orsucci, Luigi Rigacci, Eleonora Russo, Vittorio Stefoni, Alessandra Tucci, Umberto Vitolo

Blood (2010) 116 (21): 3965.

https://doi.org/10.1182/blood.V116.21.3965.3965

Published: 2010

Journal Articles

COMPARISON Among Citology, Histology, and FLOW Cytometry IN Evaluating Blast VALUES IN Myelodysplatic Syndromes (MDS). Survey FROM the Italian “PIEMONTE MDS REGISTRY”

Blood (2010) 116 (21): 4028.

https://doi.org/10.1182/blood.V116.21.4028.4028

Published: 2010

Journal Articles

Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.

Blood (2009) 114 (22): 1662.

https://doi.org/10.1182/blood.V114.22.1662.1662

Published: 2009

Journal Articles

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Blood (2009) 114 (22): 2316.

https://doi.org/10.1182/blood.V114.22.2316.2316

Published: 2009

Journal Articles

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

Annalisa Chiappella, Benedetta Puccini, Marianna Rossi, Simone Ferrero, Luca Arcaini, Ernesta Audisio, Ileana Baldi, Carola Boccomini, Barbara Botto, Fabbri Alberto, Chiara Frairia, Roberto Freilone, Marco Ladetto, Domenico Novero, Marco Paulli, Patrizia Pregno, Giorgio Priolo, Luigi Rigacci, Umberto Vitolo

Blood (2009) 114 (22): 2928.

https://doi.org/10.1182/blood.V114.22.2928.2928

Published: 2009

Journal Articles

The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi.

Annalisa Chiappella, Patrizia Pregno, Pier Luigi Zinzani, Fabio Facchetti, Andrea Evangelista, Alberto Fabbri, Andres JM Ferreri, Silvia Franceschetti, Roberto Freilone, Livio Gargantini, Daniela Gioia, Anna Marina Liberati, Lorella Orsucci, Luigi Rigacci, Eleonora Russo, Vittorio Stefoni, Alessandra Tucci, Umberto Vitolo

Blood (2009) 114 (22): 3758.

https://doi.org/10.1182/blood.V114.22.3758.3758

Published: 2009

NARROW

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Radiotherapy Consolidation Reduces Risk of Relapse in Diffuse Large B-Cell Lymphoma Patients with Bulky Disease in Complete Response after Frontline Immunochemotherapy: Results from a Retrospective Single Center Study

Clinical Outcomes of 420 MDS Patients Treated with 5-Azacytidine: Evaluation of Overall Survival, Duration of Treatment and Rate of Discontinuation in a Real Life Study from the Italian MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM)

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP

A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study

Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi

Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi

High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study

Radioimmunotherapy (RIT) with 90 yttrium Zevalin Followed by BEAM Conditioning Regimen (Z-BEAM) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of High Risk Relapsed/Resistant Non Hodgkin's Lymphoma (NHL)

Prognostic Impact of Comorbidities In A Cohort of 788 MDS Patients Based On A CIRS-G Derived Score. A MDS Piedmont Registry Prospective Study

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Weekly Infusion of Bortezomib In Combination with Rituximab In Relapsed/Refractory Indolent Non-Follicular and Mantle Cell Lymphoma Is Safe and Effective: Two-Years Analysis of Phase II Trial BRIL06 of Intergruppo Italiano Linfomi (IIL)

COMPARISON Among Citology, Histology, and FLOW Cytometry IN Evaluating Blast VALUES IN Myelodysplatic Syndromes (MDS). Survey FROM the Italian “PIEMONTE MDS REGISTRY”

Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.

Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only